Skip to main content

Advertisement

Log in

Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

We previously demonstrated the efficacy of single-dose 6-monthly rituximab infusions in 25 adults with steroid-dependent minimal-change nephrotic syndrome. Herein, we assessed the safety of rituximab treatment and its effect in ameliorating the adverse effects of prednisolone (PRED) in a larger study sample.

Methods

We treated 54 adult patients with four single-dose 6-monthly infusions of rituximab (375 mg/m2 BSA per dose). We compared the adverse effects of PRED (osteoporosis, hypertension, and diabetes mellitus) between the first rituximab infusion (baseline) and the end of the 24-month observation period. In addition, we examined the adverse effects of rituximab during the same period.

Results

The PRED dose was significantly lower at 24 months than at the baseline. The bone density was significantly higher at 24 months as compared to the baseline value (Z score −1.8 vs. −1.1; p < 0.05). Blood pressure at 24 months was significantly lower than that at the baseline (120.9/74.4 vs. 111.8/70.3 mm Hg; p < 0.05). Eight patients with diabetes mellitus showed improved glycemic control at 24 months as compared to that at the baseline. There were no severe adverse effects of rituximab. However, mild infusion reactions occurred in 31 patients (57 %). The frequency of the infusion reactions decreased significantly with every successive infusion.

Conclusion

Rituximab treatment was effective and safe in patients with steroid-dependent nephrotic syndrome, allowed reduction of the PRED dose, and ameliorated the adverse effects of PRED. It may be preferentially used in patients at a risk of the adverse effect of PRED.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset nephritic syndrome: a long-term follow-up. Kidney Int. 1986;29:1215–23.

    Article  CAS  PubMed  Google Scholar 

  2. Korbet S, Schwartz MM, Lewis EJ. Minimal-change glomerulopathy of adulthood. Am J Nephrol. 1988;8:291–7.

    Article  CAS  PubMed  Google Scholar 

  3. Eastell R. Management of corticosteroid-induced osteoporosis. UK consensus group meeting on osteoporosis. J Intern Med. 1995;237:439–47.

    Article  CAS  PubMed  Google Scholar 

  4. Sambrook PN. Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res. 2000;15:1645–9.

    Article  CAS  PubMed  Google Scholar 

  5. Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol. 1996;14:199–206.

    CAS  PubMed  Google Scholar 

  6. Jardinet D, Lefèbvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford). 2000;39:389–92.

    Article  CAS  Google Scholar 

  7. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: amulticentric series of 22 cases. Pediatr Nephrol. 2008;23:1269–79.

    Article  PubMed  Google Scholar 

  8. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321–8.

    Article  PubMed  Google Scholar 

  9. Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? Nephrol Dial Transpl. 2007;22:2100–2.

    Article  Google Scholar 

  10. François H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis. 2007;49:158–61.

    Article  PubMed  Google Scholar 

  11. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007;356:2751–2.

    Article  CAS  PubMed  Google Scholar 

  12. Sellier-Leclerc AL, Macher MA, Loirat C, Guérin V, Watier H, Peuchmaur M, Baudouin V, Deschênes G. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109–15.

    Article  PubMed  Google Scholar 

  13. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transpl. 2012;27:1910–5.

    Article  CAS  Google Scholar 

  14. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T, Kaneko K. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25:539–44.

    Article  PubMed  Google Scholar 

  15. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM. Short-term effects of rituximab in children with steroid- and calcineurindependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:1308–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–81.

    Article  CAS  PubMed  Google Scholar 

  17. Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, Tsuruta Y, Ochi A, Amemiya N, Mochizuki T, Uchida K, Tsuchiya K, Nitta K. Effect of single-dose rituximab on steroid-dependent minimal change nephrotic syndrome in adults. Nephrol Dial Transpl. 2013;28:1225–32.

    Article  CAS  Google Scholar 

  18. Iwabuchi Y, Takei T, Moriyama T, Itabashi M, Nitta K. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore). 2014;93:e300.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, Deschênes G, Ronco PM, Plaisier EM, Dahan KY. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83:511–6.

    Article  CAS  PubMed  Google Scholar 

  20. Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G, Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Miyazaki K, Sugimoto K, Tsuji S, Iharada A, Fujita S, Yanagida H, Sakata N, Okada M, Kaneko K, Takemura T. GSTT1 gene abnormality in minimal change nephrotic syndrome with elevated serum immunoglobulin E. Clin Nephrol. 2012;77:261–6.

    Article  CAS  PubMed  Google Scholar 

  22. Leandro MJ, Cambridge G, Ehrenstein MR, Edwars JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613–20.

    Article  CAS  PubMed  Google Scholar 

  23. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3: 85ra46.

  24. Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015;. doi:10.1002/14651858.

    Google Scholar 

  25. Takei T, Itabashi M, Tsukada M, Sugiura H, Moriyama T, Kojima C, Shiohira S, Shimizu A, Karasawa K, Amemiya N, Kawanishi K, Ogawa T, Uchida K, Tsuchiya K, Nitta K. Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome. Intern Med. 2010;49:2065–70.

    Article  CAS  PubMed  Google Scholar 

  26. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P, Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Can M, Alibaz-Öner F, Yılmaz-Öner S, Atagündüz P, İnanç N, Direskeneli H. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience. Clin Rheumatol. 2013;32:87–90.

    Article  PubMed  Google Scholar 

  28. Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Rapid infusion rituximab for maintenance therapy: is it feasible? Leuk Res Treat. 2013;. doi:10.1155/2013/629283.

    Google Scholar 

  29. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–73.

    Article  CAS  PubMed  Google Scholar 

  30. Shirakawa H, Ishida H, Shimizu T, Omoto K, Iida S, Toki D, Tanabe K. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transpl. 2011; 25: 878–84.

Download references

Acknowledgments

The physicians participating in this study other than the authors were as follows: Ari Shimizu, Hiroshi Kataoka, Yuki Tsuruta, Ayami Ino, Masayo Sato, Miki Nishida, Mitsuyo Itabashi, Toshio Mochizuki, Ken Tsuchiya, and Keiko Uchida (Tokyo Women’s Medical University, Tokyo).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Takashi Takei.

Ethics declarations

Conflict of interest

The authors declare that no conflict of interest exist.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyabe, Y., Takei, T., Iwabuchi, Y. et al. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome. Clin Exp Nephrol 20, 103–110 (2016). https://doi.org/10.1007/s10157-015-1139-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-015-1139-6

Keywords

Navigation